Brokerages Set Adaptimmune Therapeutics plc (NASDAQ:ADAP) Price Target at $2.18

Shares of Adaptimmune Therapeutics plc (NASDAQ:ADAP - Get Free Report) have been assigned a consensus rating of "Moderate Buy" from the five brokerages that are currently covering the firm, MarketBeat Ratings reports. One research analyst has rated the stock with a hold recommendation and four have given a buy recommendation to the company. The average 12-month target price among analysts that have covered the stock in the last year is $2.18.

ADAP has been the topic of a number of research analyst reports. Mizuho dropped their target price on shares of Adaptimmune Therapeutics from $3.00 to $1.50 and set an "outperform" rating on the stock in a research note on Wednesday, November 27th. Scotiabank reduced their price objective on Adaptimmune Therapeutics from $3.15 to $1.40 and set a "sector outperform" rating on the stock in a report on Friday. StockNews.com initiated coverage on Adaptimmune Therapeutics in a report on Friday. They issued a "buy" rating for the company. Finally, Wells Fargo & Company dropped their price target on Adaptimmune Therapeutics from $2.00 to $1.50 and set an "equal weight" rating on the stock in a research report on Friday.

Adaptimmune Therapeutics Trading Down 9.7 %

ADAP traded down $0.03 during trading hours on Friday, reaching $0.25. 3,079,887 shares of the company's stock traded hands, compared to its average volume of 1,687,471. The firm has a 50-day moving average price of $0.53 and a 200 day moving average price of $0.69. The firm has a market capitalization of $63.97 million, a PE ratio of -1.14 and a beta of 2.52. The company has a quick ratio of 3.82, a current ratio of 3.85 and a debt-to-equity ratio of 0.62. Adaptimmune Therapeutics has a 52-week low of $0.26 and a 52-week high of $1.65.

Remove Ads

Adaptimmune Therapeutics (NASDAQ:ADAP - Get Free Report) last issued its earnings results on Monday, March 24th. The biotechnology company reported ($0.26) earnings per share (EPS) for the quarter, missing analysts' consensus estimates of ($0.17) by ($0.09). The company had revenue of $3.22 million for the quarter, compared to analysts' expectations of $16.56 million. Adaptimmune Therapeutics had a negative net margin of 25.43% and a negative return on equity of 74.15%. As a group, sell-side analysts predict that Adaptimmune Therapeutics will post -0.14 EPS for the current fiscal year.

Institutional Investors Weigh In On Adaptimmune Therapeutics

Hedge funds have recently made changes to their positions in the stock. Long Focus Capital Management LLC raised its holdings in Adaptimmune Therapeutics by 54.1% in the fourth quarter. Long Focus Capital Management LLC now owns 20,494,393 shares of the biotechnology company's stock worth $11,040,000 after purchasing an additional 7,194,503 shares in the last quarter. Two Seas Capital LP purchased a new position in shares of Adaptimmune Therapeutics in the 4th quarter worth approximately $7,992,000. Renaissance Technologies LLC raised its stake in shares of Adaptimmune Therapeutics by 52.5% during the 4th quarter. Renaissance Technologies LLC now owns 2,526,524 shares of the biotechnology company's stock worth $1,361,000 after acquiring an additional 869,949 shares in the last quarter. Rock Springs Capital Management LP lifted its position in Adaptimmune Therapeutics by 2.4% during the fourth quarter. Rock Springs Capital Management LP now owns 2,483,468 shares of the biotechnology company's stock valued at $1,338,000 after acquiring an additional 58,000 shares during the last quarter. Finally, FMR LLC grew its stake in Adaptimmune Therapeutics by 3.0% during the 3rd quarter. FMR LLC now owns 1,740,900 shares of the biotechnology company's stock worth $1,655,000 after buying an additional 50,419 shares during the last quarter. 31.37% of the stock is currently owned by hedge funds and other institutional investors.

Adaptimmune Therapeutics Company Profile

Adaptimmune Therapeutics plc, a clinical-stage biopharmaceutical company, provides novel cell therapies primarily to cancer patients in the United States and the United Kingdom. It develops SPEARHEAD-1 that is in phase II clinical trials with ADP-A2M4 for synovial sarcoma; SURPASS-3 that is in phase II clinical trial with ADP-A2M4CD8 for people with platinum resistant ovarian cancer; and SURPASS that is in phase I clinical trials in patients with head and neck, and urothelial cancers.